JAK1 and type 2 diabetes mellitus: While there were no significant alterations in mROS production in HSVSMCs from both T2DM and non-diabetic patients after treatment with IL-6/sIL-6R and PDGF-BB, inhibition of JAK1/2 with ruxolitinib caused a significant reduction in the production of mROS in HSVSMCs from both T2DM and non-diabetic controls (Figure 2 and Figure 3).